ARIKAYCE® (amikacin liposome inhalation suspension)

ARIKAYCE (amikacin liposome inhalation suspension) is the first and only therapy specifically indicated for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.